David R. Walt Buys 131,869 Shares of Quanterix Co. (NASDAQ:QTRX) Stock

Quanterix Co. (NASDAQ:QTRX) Director David R. Walt purchased 131,869 shares of the firm’s stock in a transaction on Friday, June 6th. The shares were purchased at an average price of $5.43 per share, for a total transaction of $716,048.67. Following the completion of the purchase, the director now directly owns 1,628,802 shares of the company’s stock, valued at $8,844,394.86. This represents a 8.81% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Quanterix Price Performance

Quanterix stock opened at $6.66 on Thursday. Quanterix Co. has a 1-year low of $4.05 and a 1-year high of $19.18. The stock has a market cap of $258.60 million, a PE ratio of -6.28 and a beta of 1.05. The stock’s fifty day moving average is $5.30 and its two-hundred day moving average is $7.85.

Quanterix (NASDAQ:QTRX) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.16. The company had revenue of $30.33 million for the quarter, compared to analyst estimates of $28.27 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. On average, research analysts expect that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

QTRX has been the topic of a number of research reports. Scotiabank restated an “outperform” rating on shares of Quanterix in a research note on Tuesday, March 25th. Leerink Partners restated a “market perform” rating and set a $8.00 price target (down from $12.00) on shares of Quanterix in a research note on Wednesday, April 30th. Wall Street Zen cut Quanterix from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Leerink Partnrs cut Quanterix from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 30th. Finally, Canaccord Genuity Group reduced their price objective on Quanterix from $15.00 to $12.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Quanterix currently has a consensus rating of “Hold” and an average target price of $15.60.

Hedge Funds Weigh In On Quanterix

Several hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp grew its holdings in shares of Quanterix by 1.8% during the fourth quarter. Bank of New York Mellon Corp now owns 108,186 shares of the company’s stock worth $1,150,000 after buying an additional 1,963 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Quanterix by 4.2% during the first quarter. Jane Street Group LLC now owns 58,313 shares of the company’s stock worth $380,000 after buying an additional 2,366 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Quanterix by 219.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company’s stock worth $61,000 after buying an additional 3,915 shares during the last quarter. Hsbc Holdings PLC lifted its position in Quanterix by 25.8% in the fourth quarter. Hsbc Holdings PLC now owns 19,371 shares of the company’s stock valued at $205,000 after purchasing an additional 3,974 shares during the period. Finally, Canada Pension Plan Investment Board lifted its position in Quanterix by 64.5% in the fourth quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company’s stock valued at $108,000 after purchasing an additional 4,000 shares during the period. Hedge funds and other institutional investors own 86.48% of the company’s stock.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.